Skip to main content
Pathogens and Global Health logoLink to Pathogens and Global Health
. 2018 Apr 23;112(4):227–231. doi: 10.1080/20477724.2018.1460944

Assessment of Baseline Antibodies to Pandemic Influenza A/H1N1/2009 Virus in Ogbomoso, Oyo State, Nigeria

E K Oladipo a,b,*,**, E H Awoyelu a, J K Oloke a
PMCID: PMC6147097  PMID: 29683397

Introduction

Acute respiratory infection remains a global leading cause of death, with influenza accounting one of the most important causes of severe infections and deaths every year [1]. Globally, an estimated 1 million persons died from respiratory and cardiovascular conditions associated with influenza A/H1N1/2009 infections.

Transmission patterns of influenza are attached with unique epidemiologic and demographic features such as environmental, economic, religious, cultural and social conditions [2]; weather conditions such as temperate and humidity; pre-existing immunity accounting for difference in the prevalence rates of specific antibodies [3].

Serum antibody to influenza can be used to identify past exposure and measure current immune status. Various laboratory methods applied to determining the host’s immune response include haemagglutination inhibition (HI) test, neutralization test (NT), microneutralization (MN) test, and enzyme-linked immunosorbent assay (ELISA) [4]. Although both HI and NT tests serve as measures of antibody concentration in sera, they have important differences in how they are conducted and how they measure immunity.

Haemagglutination inhibition and NT assays, despite their widespread usage, the difference in reliability between laboratories is a direct result of how they are been measured [5]. These assays assess the level of functional immunity to a virus in a similar manner, both using serial dilution of sera applied to a fixed amount of virus to determine at which titer of sera the virus is effectively inhibited [6], however, the difference is in the biological mechanism used as an indicator for inhibition [7]. The HI assay utilizes the natural process of viral hemagglutination, a process in which a lattice forms by binding of viruses to red blood cells; this process is blocked when sufficient antibody with affinity to the virus is present [8]. The NT assay, in contrast, measures cytopathic effects of the virus, the invading and killing of cells, through plaque formation [9]. Again, the antibodies in the sample serum are tested for their ability to block this activity. Results are expressed as reciprocal of the highest dilution at which virus infection is blocked.

A more precise assessment of the total number of infected persons would require the large-scale use of techniques to specifically determine the presence and relative concentration of A/H1N1/2009 influenza virus antibodies in serum samples. Besides its obvious epidemiological significance, the availability of these techniques would also allow the rapid discernment of potentially immune subjects among those more susceptible to infection in a given population [5]. However, as a result of the somewhat time, labour intensive, specialized training, less availability of specific reagents needed for these techniques, hence, the assessment of specific baseline antibodies to A/H1N1/2009 influenza virus with an ELISA-based method for sero-epidemiological study among randomly-selected apparently healthy individuals.

The immunoassay used for this study shows significant advantages over conventional MN and HI assays; (i) it does not require fresh chicken erythrocytes; (ii) it does not require virus manipulation and therefore does not require special infrastructure; and (iii) interpretation of results rests on absorbance readings, instead of subjective visual estimation of agglutination.

Materials and methods

Study area

The study was carried out at the Bowen University Teaching Hospital situated at Ogbomoso, Oyo State in the tropical belt of Southern Western part of Nigeria (Africa). Its coordinates are 8º7ʹ60ʺN and 4º16ʹ0ʺE in DMS (Degrees Minutes Seconds) or 8.13333 and 4.26667 (in decimal degrees).

Study population

Consenting apparently healthy individuals, in the age range 16–65 years, attending Bowen University Teaching Hospital at Ogbomoso were enrolled for this study between December 2014 and September 2015. Structured questionnaires about demographic characteristics and other relevant information were administered to all participating subjects as well as verbal and informed consent form prior blood sample collection. No documentation of recent travel activity was obtained in the study.The study protocol was in accordance with the amended Declaration of Helsinki.

Ethical clearance

Ethical approval for the study was obtained from the Ethics Review Board of Bowen University Teaching Hospital, Ogbomoso. Informed consent was obtained from all subjects recruited into the study.

Eligibility criteria

Any individual who refused to give consent as well as provide necessary information on the questionnaire was excluded from the study. Individuals within the age range 1–14 years were excluded from the study because their parents were not ready to give consent. Clinical history of volunteers was noted, especially blood transfusion, exposure to syringes, surgical and dental procedures. Apparently unhealthy or malnourished individuals were excluded.

Collection of blood sample

Five ml of venous blood samples were collected in tubes with no anticoagulant. The blood sample was spun in a bench centrifuge at 3000 rpm for 10 min to obtain serum. Serum was obtained and stored at −20 °C until ready for analysis.

Antibody detection

Commercially available validated third generation ELISA kits (WKEA MED SURPLUS CORP, China) were employed to determine specific antibodies against influenza A (H1N1) according to the manufacturer’s instructions. The Microwell plate had been coated with recombinant influenza A/H1N1 antigens. The specificity and sensitivity of the kit were 99.55% and 99.79% respectively. The optical density was read using the Emax endpoint ELISA microplate reader (Molecular Devices, California, USA) and the result was interpreted according to the manufacturer’s instruction.

Statistical analysis

The prevalence of antibodies to influenza A (H1N1) was determined from the proportion of the positive individuals in the total population studied and expressed as percentages. The data obtained were analyzed using a Statistical Package for Social Sciences (SPSS version 20). They were organized and summarized in terms of frequencies and the results of the study were presented in tables. Chi-square (χ2) test was utilized to assess the association between the socio-demographic variables and influenza A (H1N1) status. Statistical significance was set at P ˂ 0.05. Logistic regression was done to determine the strength of association between the potential risk factors and influenza A (H1N1) status.

Results

The study includes 186 participants consisting of 93 males and females respectively. The participants were in the age range 16–65 years with a mean age of 31.62 ± 7.85 years. The sociodemographic characteristics of the participants are shown in Table 1. Overall, 8 (4.3%) out of 186 participants had antibodies to H1N1 (Table 2). As shown in Table 3, 6 (6.5%) of males were seropositive while 2 (2.2%) were positive for females. However, sex distribution had no statistical significance on the seroprevalence among the study individuals (P˃0.05). Participants in the age range 16–25 years had the highest prevalence of 10.2% compared to 3.1% and 2.1% in the age groups 36–45 and 26–35 years respectively. There was no statistically significant effect of age on H1N1 seroprevalence. Occupation wise, the highest prevalence was recorded among the students (11.9%) compared to 4.3% and 1.9% among the traders and civil servants respectively. Education wise, the highest prevalence was recorded among those that had a tertiary education (5.7%) compared to 5.9% and 2.3% among those that had other and secondary education respectively. Considering the marital status, participants who were single had a higher prevalence of 11.1% than those in the monogamy group who had a prevalence of 2.3%. There was the statistical significance of marital status on H1N1 seroprevalence (p = 0.03).

Table 1.

Socio-demographic factors of the study participants.

Parameter Age range Frequency Percentage
Age 16–25 49 26.3
26–35 95 51.1
36–45 32 17.2
46–55 9 4.3
56–65 1 0.5
Sex Male 93 50
Female 93 50
Marital status Monogamy 132 71.0
Polygamy 9 4.8
Single 45 24.2
Occupation Artisan 34 18.3
Civil servant 54 29.0
Student 42 22.6
Trader 47 25.3
Others 1 0.5
None 8 4.3
Education Primary 17 9.1
Secondary 44 23.7
Tertiary 106 57.0
Others 17 9.1
None 2 1.1

Table 2.

Seroprevalence of H1N1 infections among the study participants.

Status Total (%)
Reactive 8 (4.30)
Non-reactive 178 (95.70)
Total 186(100.00)

Table 3.

Association of H1N1 infection with sociodemographic factors.

Parameter Level IgM Sero-Status
Df Chi-square P-value
Reactive Non-reactive
Count (%) Count (%)
Age 15–25 5 10.2 44 89.8 4 5.818 0.213
26–35 2 2.1 93 97.9
36–45 1 3.1 31 96.9
46–55 0 0.0 9 100.0
56–65 0 0.0 1 100.0
Sex Male 6 6.5 87 93.6 1 2.090 0.148
Female 2 2.2 91 97.9
Marital status Monogamy 3 2.3 129 97.7 2 6.794 0.033*
Polygamy 0 0.0 9 100.0
Single 5 11.1 40 88.9
Occupation Artisan 0 0.0 34 100.0 5 8.619 0.125
Civil servant 1 1.9 53 98.2
Student 5 11.9 37 88.1
Traders 2 4.3 45 95.7
Others 0 0.0 1 100.0
None 0 0.0 8 100.0
Education Primary 0 0.0 17 100.0 4 1.873 0.759
Secondary 1 2.3 43 97.7
Tertiary 6 5.7 100 94.3
Others 1 5.9 16 94.1
None 0 0.00 2 100.0

The possible risk factor that might be associated with acquiring H1N1 infection was analyzed (Table 4). There was no statistical association between H1N1 and the risk factor (P˃0.05). The result showed that 8(4.5%) of the participant with no history of blood transfusion had H1N1, however, there was no statistical significance with the infection (χ 2 = 0.327, df = 1, p = 0.706). There was a 1-fold risk of getting infected among those who had the previous history of blood transfusion (95% CI = 0.933–0.990, OR = 1.0).

Table 4.

Association of potential risk factor and H1N1.

Variables IgM Sero-status OR 95% Cl p-value
Positive N (%) Negative N (%)
History of blood transfusion No 8 (4.5) 171 (95.5) 0.961 0.933–0.990 0.706
Yes 0 (0.0) 7 (100.0) 1    

Discussion

In this study, the overall prevalence of antibodies against influenza A (H1N1) virus was 4.3%. The presence of the antibodies in the seropositive individuals may be as a result of increased activities such as traveling, gatherings for social and group activities which create ideal conditions for the transmission of the virus. The recorded prevalence is lower than a 31% prevalence recorded in South Africa [10], 29% prevalence recorded in the metropolitan area of Buenos Aires of Argentina [11] and 25% prevalence recorded in Tampa Bay Florida [3]. The differences might be related to the methodological differences in the type and period of sample collection, diagnosis and differences in geographic location since factors such as overcrowding, climate, and personal hygiene, can affect the transmission efficiency of the virus [1]. Also, the variation in the epidemiology of circulating subtypes between countries might also explain the different findings in the seroprevalence studies [12].

There was a wide variation in the seropositive level against the A (H1N1) virus among the different age groups. Seroprevalence in subjects aged 15–25 years was 10.2%, 26–35 years was 2.1%, while it was 3.1% in the age range 36–45 years. The 15–25 year age group (10.2%) may be attributed to schools, churches serving as gathering places and group activity for young adults which allow conditions for the spread of the virus [13]. The 26–35 (2.1%) and 36–45 (3.1%) year age groups tend to work in air-conditioned offices, use public transport, attend meetings and social functions, as well as possibly acquired partial immunity against the influenza A (H1N1) strain. This is in agreement with the reports of Bada et al., [14], Miller et al., [15], Chen et al., [16], Tian et al., [17] and Cox et al., [3] with higher notification rates in those adults younger than 50 years of age as the age-specific prevalence in this study is within that range. It is in contrast with other studies showing higher antibodies among elderly [15,18–20].

Also, there was a higher seroprevalence in males (6.5%) as compared with the females (2.2%). The seroprevalence was much higher in males who constitute the main group responsible for spreading the infection due to increased activities such as traveling which is common amongst males than females, gatherings for social and group activities which create ideal conditions for the transmission of the virus as compared to females in the study area which is in accordance with the report of Labato et al., [11]. Also, it can be as a result of differing social mixing patterns between and within age groups in males compared to their female counterpart. Although, there are uncertainties in measuring mixing patterns because it is not clear what type of contacts best describe the spread of influenza. However, there was no statistically significant difference in seroprevalence by sex.

Considering education-specific prevalence, the subjects that had the tertiary education (5.7%) had higher prevalence compared to other groups. This is consistent with the key role of young adults, especially in tertiary institutions, in the transmission which can be an important epidemiological determinant of community spread. This may also be explained by overcrowding in lecture halls as well as hostels for students which create an easy contraction of the virus. This observation is in accordance with the reports of Hardelid et al., [21] and Chen et al., [16].

Considering marital status, the singles (11.1%) had high antibodies against A/H1N1/2009 as compared to the other groups (monogamy and polygamy). Singles are generally involved in more social functions and movement as compared with monogamy and polygamy groups in the study area. Interestingly, antibody seroprevalence rates were statistically significant (p = 0.033).

Considering occupational status, students exhibited 11.9% seroprevalence. This may be explained by schools serving as gathering places for students, unhygienic conditions such as lack of or improper hand washing and good personal hygiene, the use of public transport, and religious and social meetings or functions, all of which favour transmission of the virus. This is consistent with the findings of Reed et al., [22]. Also, seropositivity was not statistically associated with the previous history of blood transfusion.

Summarily, the result revealed more prevalence amongst male tertiary students within the age range 15–25 years who were single. This result is in accordance with the transmission pattern of influenza A/H1N1/2009 which is common among young adults owing to various outdoor and indoor activities they get involved.

In conclusion, rapid diagnosis of influenza virus antibodies benefits infected individuals in allowing timely therapy for proper prevention of complications; benefits public health to prevent outbreaks and further spread of the virus.

Authors’ contribution

OEK collaborated on project conception, analyzed data and wrote the draft article, AEH and OJK collaborated on project conception, statistical analysis and helped in writing the article.

Disclosure statement

The authors declare they have no conflicting interest.

Acknowledgments

The authors are thankful to those that participated in the study and the team of virology at the Prof J.K. Oloke Microbiology Research Laboratory for their dedicated work.

References

  • [1]. Ng S, Gordon A. Influenza burden and transmission in the tropics. Curr Epidemol Rep. 2015;2:89–100. 10.1007/s40471-015-0038-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [2]. Prachayangprecha S, Makkoch J, Payungporn S, et al. Serological analysis of human pandemic influenza (H1N1) in Thailand. J Health Popul Nutr. 2010;28(6):537–544. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [3]. Cox CM, Goodin K, Fisher E, et al. Prevalence of 2009 Pandemic Influenza A (H1N1) Virus Antibodies, Tampa Bay Florida November–December, 2009. PLoS One. 2011;6(12):e29301. 10.1371/journal.pone.0029301 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [4]. Zhu-Nan L, Seh-Ching L, Carney PJ, et al. IgM, IgG, and IgA antibody responses to influenza A(H1N1)pdm09 Hemagglutinin in infected persons during the first wave of the 2009 Pandemic in the United States. Clin Vacc Immunol. 2014;21(8):1054–1060. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [5]. Truelove S, Zhu H, Lessler J, et al. A comparison of hemagglutination inhibition and neutralization assays for characterizing immunity to seasonal influenza A. Influenza Other Respiratory Viruses. 2016;10:518–524. doi: 10.1111/irv.12408. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [6]. Centers for Disease Control and Prevention Antibodies cross-reactive to influenza A (H3N2) variant virus and impact of 2010–11 seasonal influenza vaccine on cross-reactive antibodies – United States. Atlanta, GA: Centers for Disease Control and Prevention; 2012. [Google Scholar]
  • [7]. Hobson D, Curry RL, Beare AS, et al. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond). 1972;70:767–777. 10.1017/S0022172400022610 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [8]. De Jong JC, Palache AM, Beyer WEP, et al. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol. 2003;115:63–73. [PubMed] [Google Scholar]
  • [9]. Bauman R. Chapter 17. Immunization and immune testing In: Microbiology with diseases by body system. 4th ed. New York (NY): Benjamin-Cummings; 2008. p.  550–750. [Google Scholar]
  • [10]. Ntshoe GM, McAnerney JM, Tempia S, et al. Influenza epidemiology and vaccine effectiveness among patients with influenza-like illness, viral watch sentinel sites, South Africa, 2005–2009. PLoS One. 2014;9(4):e94681. 10.1371/journal.pone.0094681 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [11]. Labato MI, Contrini MM, Lazzarini D, et al. Pandemic influenza A/H1N1 2009 antibodies in the metropolitan area of Buenos Aires in Argentina. Intl J Infect Dis. 2014;19:20–25. 10.1016/j.ijid.2013.09.021 [DOI] [PubMed] [Google Scholar]
  • [12]. Dudareva S, Schweiger B, Thamm M, et al. Prevalence of antibodies to 2009 pandemic influenza A (H1N1) virus in german adult population in pre- and post-pandemic period. PLoS One. 2011;6(6):e21340. 10.1371/journal.pone.0021340 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [13]. Bandaranayake D, Huang QS, Bissielo A, et al. Risk factors and immunity in a nationally representative population following the 2009 influenza A (H1N1) pandemic. PLoS One. 2010;5:e13211. 10.1371/journal.pone.0013211 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [14]. Buda S, Kopke K, Haas W. Epidemiological characteristics of the influenza pandemic (H1N1) 2009 in Germany based on the mandatory notification of cases. BundesgesundheitsblattGesundheitsforschung Gesundheitsschutz. 2010;53:1223–1230. 10.1007/s00103-010-1158-0 [DOI] [PubMed] [Google Scholar]
  • [15]. Miller E, Hoschler K, Hardelid P, et al. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross sectional serological study. Lancet. 2010;375:1100–1108. 10.1016/S0140-6736(09)62126-7 [DOI] [PubMed] [Google Scholar]
  • [16]. Chen MI, Lee VJ, Lim WY, et al. 2009 Influenza A (H1N1) seroconversion rates and risk factors among distinct adult cohorts in Singapore. JAMA. 2010;303:1383–1391. 10.1001/jama.2010.404 [DOI] [PubMed] [Google Scholar]
  • [17]. Tian LL, Shi WX, Ying D, et al. Serologic survey of pandemic influenza A (H1N1 2009) in Beijing, China. Prev Med. 2010;52:71–74. [DOI] [PubMed] [Google Scholar]
  • [18]. Zimmer SM, Crevar CJ, Carter DM, et al. Seroprevalence following the second wave of Pandemic 2009 H1N1 influenza in Pittsburgh, PA, USA. PLoS One. 2010;5:e11601. 10.1371/journal.pone.0011601 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [19]. Skowronski DM, Hottes TS, Janjua NZ, et al. Prevalence of seroprotection against the pandemic (H1N1) virus after the 2009 pandemic. CMAJ. 2010;182:1851–1856. 10.1503/cmaj.100910 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [20]. Xu C, Bai T, Iuliano AD, et al. The seroprevalence of pandemic influenza H1N1 (2009) virus in China. PLoS One. 2011;2011(6):e17919. 10.1371/journal.pone.0017919 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [21]. Hardelid P, Andrews NJ, Hoschler K, et al. Assessment of baseline age-specific antibody prevalence and incidence of infection to novel influenza A/H1N1 2009. Health Technol Assessment. 2010;14(55):115–192. [DOI] [PubMed] [Google Scholar]
  • [22]. Reed C, Katz JM, Hancock K, et al. Prevalence of seropositivity to pandemic influenza A/H1N1 virus in the United States following the 2009 Pandemic. PLoS One. 2012;7(10):e48187. doi: 10.1371/journal.pone.0048187. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Pathogens and Global Health are provided here courtesy of Taylor & Francis

RESOURCES